Skip to main content

Table 1 Demographic and descriptive characteristics of study participants

From: Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes

 

HDL ≤ 40 mg/dL

HDL = 40–60 mg/dL

LDL

≤100 mg/dL

100-130 mg/dL

130–160 mg/dL

≥160 mg/dL

LDL Not Measured

≤100 mg/dL

100–130 mg/dL

130–160 mg/dL

HIV Status

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

n

17

46

12

27

19

7

3

4

1

7

23

15

19

11

17

12

Median

Age (years)

51

48.5

53

48

45

55

40

46.5

56

46

48

46

50

50

48

46

BMI

31.6

25.2

27.8

25.2

28

23.9

27.5

30.2

30.6

23.4

27.1

24.7

26.4

24.8

26.9

24.2

HDL (mg/dL)

34

29.1

34.5

31

36

34

37

35.9

28

28.6

50

48.2

50

48

51

46.7

LDL (mg/dL)

78

78.5

121

115

145

142

172

175

130

–

76

86

112

110

145

140

TCHOL (mg/dL)

153

143

189

188

213

214

241

253

181

182

146

151

185

187

215

225

TRIG (mg/dL)

203

197

205

225

152

156

132

148

114

434

81

102

110

108

101

178

# on therapy

No therapy

–

12

–

9

–

2

–

1

–

2

–

3

–

–

–

2

Mono-therapy

–

–

–

–

–

 

–

–

–

–

–

–

–

1

–

–

Combination

–

5

–

1

–

 

–

–

–

–

–

–

–

–

–

–

Potent ART

–

29

–

17

–

5

–

3

–

5

–

12

–

10

–

10

Therapy adherence

100 %

–

10

–

7

–

3

–

2

–

–

–

3

–

4

–

5

95–99 %

–

19

–

8

–

2

–

1

–

5

–

8

–

6

–

4

<75 %

–

3

–

2

–

 

–

–

–

–

–

1

–

–

–

1

NA

–

14

–

10

–

2

–

1

–

2

–

3

–

1

–

2

BGA

AEA

–

4

3

5

4

–

–

1

–

–

6

3

7

2

1

2

AsEA

1

2

–

–

–

–

–

–

–

1

–

–

–

–

2

1

EA

15

39

8

22

15

7

3

3

1

6

16

12

12

9

14

9

NA

1

1

1

–

–

–

–

–

–

–

1

–

–

–

–

–

Group total

17

46

12

27

19

7

3

4

1

7

23

15

19

11

17

12

 

HDL = 40–60 mg/dL

HDL ≥ 60 mg/dL

  

LDL

≥160 mg/dL

LDL not measured

≤100 mg/dL

100–130 mg/dL

130–160 mg/dL

≥160 mg/dL

LDL not measured

  

HIV Status

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

  

n

13

4

1

1

8

15

8

7

2

6

3

6

1

4

  

Median

  

Age (years)

50

49

22

52

45

42

46.5

52

53.5

47

59

47

31

45.5

  

BMI

27.8

26.2

20.7

27.4

25.7

22.9

24.8

23.9

27.3

22.6

26.6

22.5

22.7

24.7

  

HDL (mg/dL)

51

45

54.6

40.6

73.5

76.1

63.3

75.9

64.3

82.4

62.5

68.5

60

71.8

  

LDL (mg/dL)

165

175

–

–

92.5

80

119

111

138

144

167

167

130

–

  

TCHOL (mg/dL)

245

251

163

176

181

181

203

205

223

249

247

259

224

236

  

TRIG (mg/dL)

134

122

–

–

86

103

104

94

101

102

105

98

168

525

  

# on therapy

  

No therapy

–

–

–

–

–

4

–

1

–

2

–

2

–

–

  

Mono-therapy

–

–

–

–

–

–

–

–

–

–

–

–

–

–

  

Combination

–

–

–

–

–

2

–

–

–

–

–

–

–

–

  

Potent ART

–

4

–

1

–

9

–

6

–

4

–

4

–

4

  

Therapy adherence

  

100 %

–

2

–

–

–

5

–

1

–

–

–

3

–

2

  

95–99 %

–

2

–

–

–

3

–

4

–

2

–

 

–

2

  

<75 %

–

–

–

1

–

3

–

1

–

2

–

1

–

–

  

NA

–

–

–

–

–

4

–

1

–

2

–

2

–

–

  

BGA

  

AEA

3

–

1

–

1

11

3

–

–

4

–

–

–

1

  

AsEA

–

–

–

–

1

3

–

–

–

–

–

–

–

1

  

EA

10

4

–

1

6

1

5

7

2

2

3

5

1

2

  

NA

–

–

–

–

–

–

–

–

–

–

–

1

–

–

  

Group total

13

4

1

1

8

15

8

7

2

6

3

6

1

4

  
  1. BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TCHOL, total cholesterol; TRIG, triglycerides; monotherapy, single nucleoside reverse transcriptase inhibitor; Combination, two or more nucleoside reverse transcriptase inhibitors; potent ART, two or more nucleoside reverse transcriptase inhibitors with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor; BGA, biogeographical ancestry; AEA, African/European ancestry; EA, European ancestry; AsEA, Asian European ancestry
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us